+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 6Years +
All Genders
ID04183101

Phase 2 Cross-over Study Comparing Oral Aliskiren and Enalapril for Treatment of C3 Glomerulopathy in Children and Adults

Led by Region Skane · Updated on 2025-06-22

30

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating aliskiren, a direct renin inhibitor, as a new treatment option for patients with C3 glomerulopathy, a kidney disease caused by complement system activation. This study compares aliskiren to the current standard treatment, enalapril, an angiotensin converting enzyme inhibitor ACEi. The goal is to see if aliskiren can better reduce complement activation in the kidneys, which may stabilize or improve kidney function. This is a phase 2, randomized, open-label, controlled cross-over trial involving patients with this complement-mediated renal disease. Participants will be randomly assigned to start treatment with either aliskiren tablets 150-300 mg daily or enalapril tablets 2.5-20 mg daily for the first 6 months. After this period, they will switch to the other treatment for the next 2.5 years, completing a total of 3 years of treatment. Dosing schedules may vary between once or twice daily depending on the medication and patient weight. The study also includes an extension phase with repeat kidney biopsies to assess complement deposition and kidney tissue changes. During the study, patients will have routine follow-up visits every 3 months with their own nephrologist. These visits will include blood and urine tests to monitor kidney function, protein levels, renin and complement system activity using various assays. Kidney biopsies will be performed at the start and again after 1 to 3 years to evaluate treatment effects on kidney structure. The study measures primary outcomes such as serum C3 levels and complement deposits in the kidneys, along with secondary outcomes like proteinuria, blood pressure, and other complement activation markers.

CONDITIONS

Brief Title

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Research Team

D

Diana Karpman, MD PhD

Z

Zivile Bekassy, MD PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here